Serum Long-Noncoding RNA H19 and β-Catenin as Biomarkers for Early Diagnosis of Colorectal Cancer in Egyptian Patients: A Case Control Study

Elshazly, Ayat Abdelrahman Abdelrahman; Desouky, Mohammed Nageeb; Diab, Iman Hassan; Ibrahim, Abeer Mahmoud Ali; Dwedar, Fatma Ibrahim

doi:10.1055/s-0042-1742668

Acessibilidade / Reportar erro

Brasil

Journal of Coloproctology (Rio de Janeiro)

Español English

Brasil

Español English

sumário « anterior atual seguinte »

Sumário

Original Article • J Coloproctol 42 (3) • 2022 • https://doi.org/10.1055/s-0042-1742668 copy

Serum Long-Noncoding RNA H19 and β-Catenin as Biomarkers for Early Diagnosis of Colorectal Cancer in Egyptian Patients: A Case Control Study

Authorship SCIMAGO INSTITUTIONS RANKINGS

Abstract

Colorectal cancer (CRC) is the third most prevalent cancer and the second most common cause of cancer death; however, its early detection can improve the survival. Colonic polyps are considered one of the CRC's major risk factors. Throughout many biological processes and malignancies, the non-coding RNAs have essential functions. Certain long noncoding RNAs (lncRNAs), including H19, were supposed to be CRC possible biomarkers. Also, H19 has been reported to play a role in regulating the activity of β-catenin, a protein that regulates cell-to-cell adhesion, as well as gene transcription. The current work aimed to investigate the potential significance of LncRNA H19 relative serum expression level by quantitative polymerase chain reaction (q-PCR) and β-catenin by enzyme-linked immunosorbent assay (ELISA) as noninvasive biomarkers to discriminate between colorectal cancer and colonic polyps. The statistical analysis of the studied factors revealed that the serum expression of H19 and β-catenin in cancer cases were substantially greater than colonic polyp cases and normal control.

Conclusion

The relative expressions of H19 and beta-catenin in the serum can significantly discriminate patients with CRC from those with polyp and normal controls, which could help when screening for CRC.

Keywords
LncRNA; H 19; β-catenin; CRC; colonic polyp

		Group 1 (n = 40)		Group 2 (n = 40)		Group 3 (n = 20)
		No.	%	No.	%	No.	%
Sex
	Male	17	42.5	21	52.5	5	25.0
	Female	23	57.5	19	47.5	15	75.0
Age (years)
	Min.–Max.	40.0–79.0		40.0–68.0		32.0–67.0
	Mean ± SD	55.60 ± 9.37		50.48 ± 7.29		52.95 ± 8.68
Significance		p₁= 0.021^* * Statistically significant at p ≤ 0.05. , p₂= 0.489, p₃= 0.535
HB (g/dl)
	Mean ± SD	10.16 ± 1.21		11.83 ± 1.56		12.42 ± 1.38
Significance		p₁< 0.001^* * Statistically significant at p ≤ 0.05. , p₂< 0.001^* * Statistically significant at p ≤ 0.05. , p₃= 0.278
Erythrocytic sedimentation rate (ESR) (mm/h)
Median		67.50 (28.0–96.50)		29.50 (20.0–42.50)		14.50 (10.0–21.0)
Significance		p₁= 0.007^* * Statistically significant at p ≤ 0.05. , p₂< 0.001^* * Statistically significant at p ≤ 0.05. , p₃= 0.006^* * Statistically significant at p ≤ 0.05.
Serum Albumin (g/dl)
	Mean ± SD	28.95 ± 7.33		35.74 ± 5.46		40.14 ± 3.29
Significance		p₁< 0.001^* * Statistically significant at p ≤ 0.05. , p₂< 0.001^* * Statistically significant at p ≤ 0.05. , p₃= 0.023^* * Statistically significant at p ≤ 0.05.
C- reactive protein (CRP) (mg/l)
Median		7.30 (4.0–9.10)		3.05 (2.0–4.30)		1.20 (1.0–3.25)
Significance		p₁< 0.001^* * Statistically significant at p ≤ 0.05. , p₂< 0.001^* * Statistically significant at p ≤ 0.05. , p₃= 0.049^* * Statistically significant at p ≤ 0.05.
CEA (ng/ml)
Median		8.11(6.3–11.7)		1.89 (1.24–3.2)		2.60(1.4–4.1)
Significance		p1 < 0.001^* * Statistically significant at p ≤ 0.05. , p2 < 0.001^* * Statistically significant at p ≤ 0.05. , p3 = 0.622
CA19–9 (U/ml)
Median		33.15(24.3–39.2)		7.71(2.4–15.2)		7.72(4.4–18.5)
Significance		p1 < 0.001^* * Statistically significant at p ≤ 0.05. , p2 < 0.001^* * Statistically significant at p ≤ 0.05. , p3 = 0.593

	Group I (n = 40)	Group II (n = 40)	Group III (n = 20)	P
H19 (fold increase)
Min. – Max.	0.04–10.20	0.05–9.34	0.23–4.56	0.010^* * Statistically significant at p ≤ 0.05.
Median (IQR)	1.24 (0.54–2.17)	0.70 (0.38–1.73)	0.49 (0.29–1.01)
Significance	p1 = 0.019^* * Statistically significant at p ≤ 0.05. , p2 = 0.006^* * Statistically significant at p ≤ 0.05. , p3 = 0.411
β-catenin (pg/ml)
Min.–Max.	127.0–4,520.0	99.0–3,395.0	90.50–1,009.0	0.010^* * Statistically significant at p ≤ 0.05.	0.001^* * Statistically significant at p ≤ 0.05.
Median (IQR)	305 (199.7–509.5)	211.25 (139–305)	151.0 (119.5–233.3)		0.001^* * Statistically significant at p ≤ 0.05.
Significance	p1 = 0.009^* * Statistically significant at p ≤ 0.05. , p2 < 0.001^* * Statistically significant at p ≤ 0.05. , p3 = 0.138

	AUC	P	95% C.I	Cut off	Sensitivity	Specificity	PPV	NPV
CEA	0.963^* * Statistically significant at p ≤ 0.05	< 0.001^* * Statistically significant at p ≤ 0.05	0.914–1.011	> 4.56	95.0	92.50	92.7	94.9
CA19-9	0.943^* * Statistically significant at p ≤ 0.05	< 0.001^* * Statistically significant at p ≤ 0.05	0.896–0.991	> 19.45^#	95.0	87.50	88.4	94.6
H19	0.653^* * Statistically significant at p ≤ 0.05	0.019^* * Statistically significant at p ≤ 0.05	0.532–0.774	> 0.85	67.50	62.50	64.3	65.8
Catenin	0.681^* * Statistically significant at p ≤ 0.05	0.005^* * Statistically significant at p ≤ 0.05	0.563–0.799	> 215.5	67.50	57.50	61.4	63.9
H19 + Catenin	0.724^* * Statistically significant at p ≤ 0.05	0.001^* * Statistically significant at p ≤ 0.05	0.612–0.836		35.0	87.50	73.68	57.38
CEA + H19 + Catenin	0.965^* * Statistically significant at p ≤ 0.05	< 0.001^* * Statistically significant at p ≤ 0.05	0.917–1.013		90.0	95.0	94.74	90.48
CA19-9 + H19 + Catenin	0.948^* * Statistically significant at p ≤ 0.05	< 0.001^* * Statistically significant at p ≤ 0.05	0.905–0.992		87.50	87.50	87.50	87.50

	AUC	P	95% C.I	Cut off	Sensitivity	Specificity	PPV	NPV
CEA (ng/ml)	0.976^* * Statistically significant at p ≤ 0.05.	< 0.001^* * Statistically significant at p ≤ 0.05.	0.943–1.009	> 4.6	95.0	90.0	95.0	90.0
CA19-9 (U/ml)	0.938^* * Statistically significant at p ≤ 0.05.	< 0.001^* * Statistically significant at p ≤ 0.05.	0.875–1.002	> 19.3	95.0	80.0	90.5	88.9
H19 (fold increase)	0.715^* * Statistically significant at p ≤ 0.05.	0.007^* * Statistically significant at p ≤ 0.05.	0.575–0.855	> 0.54	72.50	50.0	74.4	47.6
Catenin (pg/ml)	0.763^* * Statistically significant at p ≤ 0.05.	0.001^* * Statistically significant at p ≤ 0.05.	0.634–0.891	> 198.5	75.0	65.0	81.1	56.5

Sociedade Brasileira de Coloproctologia Av. Marechal Câmara, 160/916, 20020-080 Rio de Janeiro/RJ Brasil, Tel.: (55 21) 2240-8927, Fax: (55 21) 2220-5803 - Rio de Janeiro - RJ - Brazil
E-mail: sbcp@sbcp.org.br

Acompanhe os números deste periódico no seu leitor de RSS

[1] Address for correspondence Ayat Abdelrahman Abdelrahman Elshazly Lecturer of Medical Biochemistry, Department of Medical Biochemistry, Faculty of Medicine, Alexandria University Alexandria Egypt (e-mail: ayat_elshazly@yahoo.com).